Artur Cideciyan

[IOVS Journal @ARVOiovs]

Tomas Aleman et al. @ScheieEye @ChildrensPhila @cideciya study Retinal Degeneration Associated With Biallelic RDH12 Variants: Longitudinal Evaluation of Retinal Structure and Visual Function in Pediatric Patients, https://t.co/hBSaSAFv8S.

[Penn Medicine CSO @PennMedCSO]

New research out in @TheLancet demonstrates the safety & efficacy of ATSN-101 gene therapy for improving vision in patients with Leber congenital amaurosis caused by GUCY2D mutations ft. @cideciya & Tomas Aleman (@ScheieEye) https://t.co/YQ0aqpxkGW

[Department of Ophthalmology & Scheie Eye Institute @ScheieEye]

CHRD co-directors Dr. Cideciyan & Dr. Aleman led a gene therapy trial for LCA1, a rare retinal disease, achieving 100x sight improvement sustained for 1 year. The trial focused on ATSN-101, a subretinal gene therapy. #GeneTherapy #PennMedicine #Ophthalmology #Research #Innovation

[Artur Cideciyan @cideciya]

@NEIDirector @ScheieEye @PennMedicine @TheLancet Thank you Mike for your interest in our study that we are very excited about.

[Artur Cideciyan @cideciya]

@CuiLab Congratulations

[IOVS Journal @ARVOiovs]

Artur V. Cideciyan @cideciya et al. @ScheieEye describe a treatment strategy with gene editing for late-onset retinal degeneration caused by a founder variant in C1QTNF5.
https://t.co/cJTpB64I7b

[Artur Cideciyan @cideciya]

Excited to get started planning the Phase 1/2 trial for NPHP5 gene therapy

[@PennMedBenchmarks @PennMedBench]

A first-in-human clinical trial to treat NPHP5 Retinal Degeneration, led by Tomas Aleman, MD, Artur Cideciyan, PhD, Gustavo Aguirre, VMD, PhD & William Beltran, DVM, PhD, was selected for the BGTC Clinical Trial Portfolio, announced at @ASGCTherapy annual meeting. @ScheieEye

[Artur Cideciyan @cideciya]

Will be moving over to Mastodon soon

[IOVS Journal @ARVOiovs]

Artur Cideciyan @cideciya et al @ScheieEye evaluate rod and cone function and outer retinal structure in macular lesions and surrounding extralesional areas of patients with autosomal dominant Best vitelliform macular dystrophy caused by BEST1 mutations
https://t.co/mXVAbeOxd2

[Artur Cideciyan @cideciya]

That was a cool game. Thank you NYT. I got 5/7 from "You Be the Ump"
✅✅✅⚪️✅✅⚪️
https://t.co/EcS5LpuPDg

[Dr Lisa Nivison-Smith @LNivisonSmith]

Are you 'Excited to share my new paper!'

Harsh truth:
Most people don't care

5 tips on how to tweet about your new paper to get real engagement

@OpenAcademics @PhD_Genie @PhDVoice @AcademicChatter

[Artur Cideciyan @cideciya]

@DrLaurenAyton @Retina_Int Thank you Lauren, it was great to chat.

[Artur Cideciyan @cideciya]

@NEIDirector @pennvet @ScheieEye @fightblindness @CaseyEye I am sorry I missed William's talk. I am sure it was excellent.

[Artur Cideciyan @cideciya]

@NEIDirector @uiowaeye @uzgent @ScheieEye @PennMedicine @ProQR @NatureMedicine @ChildrensPhila @allenho @Wills_Eye @MidAtl_Retina @3Y3MD @UCLeye @ElliottSohnMD @MikeCheetham2 Indeed very exciting time for the forms of LCA like CEP290-LCA10 where some patients show large vision improvement potential due to dissociation of function from structure.

[Ophthalmology @AAOjournal]

Phase 1/2 study of CEP290 assc. LCA suggests unilateral intravitreal Sepofarsen (anti-sense oligonucleotide) improves light sensitivity in treated eye of 5 patients with light perception vision @cideciya @ScheieEye @ProQR https://t.co/NvaRmNAtD3

[Artur Cideciyan @cideciya]

Looking forward to participating

[Fighting Blindness @fight_blindness]

Retina Conference 2021: have you registered yet? Visit https://t.co/oAuVM1ZuI3 and register for free for our Scientific Day, 5th of November. Our wonderful speakers include @edelmurphy2, Bo Chen, Prof @cideciya and more. #Retina21 #conference #Retina21

[Artur Cideciyan @cideciya]

Ocular theranostics at #ARVO2021 today 3:30pm EDT.

I will present gene-based therapies in patients with CEP290-LCA and in dogs with NPHP5-LCA.
Robert Zawadzki, Jennifer Kang-Mieler, Karl Csaky, Ursula Schmidt-Erfurth, Valeria Cant…https://t.co/iY96uqLY7H https://t.co/0vWVGXP7qj

[Artur Cideciyan @cideciya]

Night vision in the RP macula – slow progress towards platform-independent measurements. Today at #ARVO2021, please visit poster by Arun Kumar Krishnan, post-doctoral fellow in my lab, describing rod function in retinitis pigmentosa obtained with MP-1S an…https://t.co/hWnyACzKGV

[Penn Medicine CSO @PennMedCSO]

A @PennMedicine patient w/ Leber congenital amaurosis- which causes genetic childhood #blindness- demonstrated sustained improvement of vision 15 mos after 1 interocular injection of #sepofarsen ft. @cideciya, Samuel Jacobson & Joan O'Brien (@ScheieEye) https://t.co/ZZvoevzjrb

[Nature Medicine @NatureMedicine]

Post hoc analyses and follow-up of a patient with Leber congenital amaurosis treated with the antisense oligonucleotide sepofarsen indicate sustained improvement of vision 15 months after receiving a single dose of the drug. @cideciya #ASO https://t.co/t9wGTwcf2q

[ProQR Therapeutics @ProQR]

Great result from our Phase 1/2 clinical trial of sepofarsen in CEP290 mediated #LeberCongenitalAmaurosis. We're looking forward to the results from the Phase 2/3 Illuminate trial next year.

#LCA10 #EyeHealth #Ophthalmology #Retina #Optometry #Ophthalmologist #Optometrist